Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes

D R Matthews, P M Paldánius, P Proot, J E Foley, M Stumvoll, S Del Prato, D R Matthews, P M Paldánius, P Proot, J E Foley, M Stumvoll, S Del Prato

Abstract

Aim: To assess the long-term clinical benefits of early combination treatment with vildagliptin-metformin vs. standard-of-care, metformin monotherapy in the ongoing VERIFY study.

Methods: We randomized 2001 participants with multi-ethnic background, aged 18-70 years, having HbA1c levels 48-58 mmol/mol (6.5-7.5%) and BMI 22-40 kg/m2 . Baseline data included HbA1c , fasting plasma glucose and homeostasis model β-cell and insulin sensitivity. Standardized meal-tests, insulin secretion rate relative to glucose, and oral glucose insulin sensitivity were assessed in a subpopulation.

Results: Out of 4524 screened, data were collected from the 2001 eligible participants (53% women) across Europe (52.4%), Latin America (26.8%), Asia (17.2%), South Africa (3.1%) and Australia (0.5%). The median (interquartile range) disease duration was 3.4 (0.9, 10.2) months; mean (±SD) age 54.3±9.4 years; weight 85.5±17.5 kg and BMI 31.1±4.7 kg/m2 . Baseline HbA1c was 52±3 mmol/mol (6.9±0.3%), fasting plasma glucose 7.5±1.5 mmol/l and the median (interquartile range) of fasting insulin was 109 (75-160) mU/l. Homeostasis model β-cell and insulin sensitivity values were 84% (60, 116) and 46% (31, 68), respectively. In those undertaking meal-tests, insulin secretion rate relative to glucose was 28±12 pmol/min/m2 /mmol/l and oral glucose insulin sensitivity was 353±57 ml/min/m2 .

Conclusions: Our current, multi-ethnic, newly diagnosed VERIFY population reflects a characteristic presence of early insulin resistance in participants with increased demand for insulin associated with obesity. The VERIFY study will provide unique evidence in characterizing therapeutic intervention in a diverse population with hyperglycaemia, focusing on durability of early glycaemic control.

Trial registration: ClinicalTrials.gov NCT01528254.

© 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

Figures

Figure 1
Figure 1
Disposition of participants screened in the VERIFY trial

References

    1. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011; 124: S19–S34.
    1. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care 2013; 36: 3411–3417.
    1. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A et al Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study. Diabetes Obes Metab 2010; 12: 780–789.
    1. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment‐naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 506–515.
    1. Del Prato S, Foley JE, Kothny W, Kozlovski P, Stumvoll M, Paldánius PM et al Study to determine the durability of glycaemic control with early treatment with a vildagliptin‐metformin combination regimen vs. standard‐of‐care metformin monotherapy‐the VERIFY trial: a randomized double‐blind trial. Diabet Med 2014; 31: 1178–1184.
    1. Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi‐Sunyer FX et al Robust improvements in fasting and prandial measures of beta‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008; 10: 931–938.
    1. Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of beta‐cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes Care 2013; 36: 2324–2330.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm ‐ 2017 executive summary. Endocr Pract 2017; 23: 207–238.
    1. Abdul‐Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E et al Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015; 17: 268–275.
    1. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug‐naïve patients with type 2 diabetes: a randomized, double‐blind, 6‐month study. Diabetes Obes Metab 2014; 16: 613–621.
    1. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes Obes Metab 2014; 16: 410–417.
    1. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double‐blind 1‐year extension study. Int J Clin Pract 2013; 67: 1283–1293.
    1. Williams‐Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ et al Effect of initial combination therapy with sitagliptin and metformin on β‐cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 67–76.
    1. Reasner C, Olansky L, Seck TL, Williams‐Herman DE, Chen M, Terranella L et al The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 644–652.
    1. Mirasol RC, Pathan MF, Chawla M, Kim TH, Cooke K, Hours‐Zesiger P et al INITIAL combination therapy with vildagliptin/metformin in drug‐naïve Asian T2DM patients: influence of age, BMI and co‐morbidities in a real‐world setting. PO‐774. Poster presented at the 53rd European Association for the Study of Diabetes Annual Meeting, 11–15 September 2017, Lisbon, Portugal.
    1. Viberti G, Kahn Se, Greene DA, Herman WH, Zinman B, Holman RR et al A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737–1743.
    1. Diabetes Prevention Program (DPP) Research Group . Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension 2002; 40: 679–686.
    1. Tan VM, Lee YS, Venkataraman K, Khoo EY, Tai ES, Chong YS et al Ethnic differences in insulin sensitivity and beta‐cell function among Asian men. Nutr Diabetes 2015; 5: e173.
    1. Harris MI, Cowie CC, Gu K, Francis ME, Flegal K, Eberhardt MS. Higher fasting insulin but lower fasting C‐peptide levels in African Americans in the US population. Diabetes Metab Res Rev 2002; 18: 149–155.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다